Table 1 Baseline characteristics of the early-stage breast cancer patients included in the study.
From: Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study
Breast cancer patients, n (%) | |
|---|---|
n | 311 |
Age at time of primary surgery | |
<50 years | 65 (21%) |
50–69 years | 197 (63%) |
≥70 years | 49 (16%) |
Tumor size | |
T1 ≤ 20 mm | 175 (56%) |
T2 > 20 ≤ 50 mm | 132 (42%) |
T3 > 50 mm | 4 (1.3%) |
Histological typea | |
Ductal | 276 (89%) |
Lobular | 15 (4.8%) |
Other | 20 (6.4%) |
Tumor grade | |
Grade I | 71 (23%) |
Grade II | 141 (45%) |
Grade III | 78 (25%) |
Unknown | 21 (6.8%) |
Lymph node metastasis | |
N0 = 0 nodes | 155 (50%) |
N1 = 1–3 nodes | 111 (36%) |
N2–3 ≥ 4 nodes | 45 (14%) |
Estrogen receptor status | |
Negative (<10%) | 58 (19%) |
Positive (10–100%) | 253 (81%) |
HER2 IHC/FISH statusb | |
Negative | 248 (80%) |
Positive | 49 (16%) |
Unknown | 14 (4.5%) |
Progesterone receptor status | |
Negative (<10%) | 91 (29%) |
Positive (10–100%) | 183 (59%) |
Unknown | 37 (12%) |
Triple negative | |
Yes | 33 (11%) |
No | 227 (73%) |
Unknown | 51 (16%) |
